Duct carcinoma in situ: 227 cases without microinvasion.

From 1979 to 1990, 227 patients with intraductal carcinomas (DCIS) without microinvasion were selectively treated; the least favourable (large lesions with involved biopsy margins) with mastectomy, the most favourable (small lesions with clear margins) with breast preservation. The preservation group was further subdivided into those who received radiation therapy (excision and radiation) and those who did not (excision alone). In the mastectomy group, there were 98 patients (43%) with an average lesional size of 3.3 cm; 41% had multifocal lesions, 15% had multicentric lesions. There has been one local invasive recurrence and no deaths. The 7-year actuarial disease-free survival is 98% with mastectomy. In the excision and radiation group, there were 103 patients (45%) with an average lesional size of 1.4 cm. 10 patients have had local recurrences (5 invasive and 5 noninvasive) one of whom has died. The 7-year actuarial disease-free survival is 84%, a statistically significant difference when excision and radiation is compared with mastectomy (P = 0.038). In the excision alone group, there were 26 patients (11%) with an average lesional size of 1.0 cm. There have been two local recurrences (8%), one of which was invasive and no deaths. The 7-year actuarial disease-free survival is 67%, but only 3 patients have been followed for more than 4 years. A total of 163 axillary node dissections were done; all were negative. Since DCIS without microinvasion rarely metastasizes to axillary lymph nodes, routine dissection should not be performed. Patients in this series with intraductal carcinoma treated with excision and radiation recurred locally at a statistically higher rate than those treated with mastectomy, in spite of the fact that those chosen for excision and radiation had clinically more favourable lesions. 6 of 12 (50%) local recurrences in conservatively treated patients were invasive. There was, however, no significant difference in overall survival in any subgroup regardless of treatment.

[1]  H. Gallager,et al.  Intraductal carcinoma of the breast. A comparative study. , 1975, American journal of surgery.

[2]  J. Hendriks,et al.  Extent, distribution, and mammographic/ histological correlations of breast ductal carcinoma in situ , 1990, The Lancet.

[3]  J. Farrow.  The James Ewing lecture current concepts in the detection and treatment of the earliest of the early breast cancers , 1970 .

[4]  S. Feig,et al.  Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment. , 1989, Archives of surgery.

[5]  W. Fletcher,et al.  Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. , 1985, American journal of surgery.

[6]  M. Silverstein,et al.  Radiation therapy for intraductal carcinoma. Is it an equal alternative? , 1991, Archives of surgery.

[7]  N. Gibbs,et al.  Importance of cellular DNA content in pre‐malignant breast disease and pre‐invasive carcinoma of the female breast , 1987, The British journal of surgery.

[8]  S. Paik,et al.  Pathologic findings from the national surgical adjuvant breast project (protocol 6) I. Intraductal carcinoma (DCIS) , 1986, Cancer.

[9]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[10]  F. Ames,et al.  The role of limited surgery with irradiation in primary treatment of ductal in situ breast cancer. , 1990, International journal of radiation oncology, biology, physics.

[11]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[12]  M. Lagios.  Duct carcinoma in situ. Pathology and treatment. , 1990, The Surgical clinics of North America.

[13]  M. Lagios,et al.  Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence , 1989, Cancer.

[14]  R. E. Snyder,et al.  Prospective study of non‐infiltrating carcinoma of the breast , 1977, Cancer.

[15]  B. Fisher.  A biological perspective of breast cancer: Contributions of the national surgical adjuvant breast and bowel project clinical trials , 1991, CA: a cancer journal for clinicians.

[16]  M. Silverstein,et al.  Nonpalpable breast lesions: diagnosis with slightly overpenetrated screen-film mammography and hook wire-directed biopsy in 1,014 cases. , 1989, Radiology.

[17]  S. Feig,et al.  Heterogeneity of intraductai carcinoma of the breast , 1989 .

[18]  A. Fourquet,et al.  Conservative management of intraductal breast carcinoma with tumorectomy and radiation therapy , 1986 .

[19]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[20]  I. Fentiman,et al.  In situ ductal carcinoma of the breast: implications of disease pattern and treatment. , 1986, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  S. Schnitt,et al.  Results of treating ductal carcinoma In situ of the breast with conservative surgery and radiation therapy , 1991, Cancer.

[22]  G. Murphy,et al.  Noninvasive Breast Carcinoma: Results of a National Survey by the American College of Surgeons , 1980, Annals of surgery.

[23]  S. Hajdu,et al.  Intraductal carcinoma of the breast (1960–1969) , 1971, Cancer.